BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
목요일, 10월 01

Adaptive Biotechnologies Corp

ADPTNASDAQ
Trade with Public
Trade with Public
$28.90
0.130.45%
가까이에: Sep 30, 5:00 PM EST
$28.98
0.080.28%
시간외: 4:02 PM EST
개요뉴스실적 전망이벤트목표가재무심리지분 현황비교옵션주식 보고서

Adaptive Biotechnologies Analyst Price Targets

Wall Street analyst price targets and consensus rating for Adaptive Biotechnologies (ADPT).

Price Target Range — 12 Quarters

Analyst Consensus — 7 Analysts

7Buy
Consensus RatingBuy# Analysts7Avg. Consensus PT$23Upside to Avg. PT-22.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →
DateFirmAnalystActionRating ChangePrice Target
Sep 29, 2026Goldman SachsEvie KosloskyInitiateBuy$35
Sep 22, 2026BTIGMark MassaroPT RaiseBuy$25→$34
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Goldman Sachs Initiates Coverage On Adaptive Biotechnologies with Buy Rating, Announces Price Target of $35

Goldman Sachs analyst Evie Koslosky initiates coverage on Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy rating and announces Price Target of $35.
Benzinga Newsdesk

PRO
BTIG Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $34

BTIG analyst Mark Massaro maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $25 to $34.
Benzinga Newsdesk

PRO
Piper Sandler Maintains Overweight on Adaptive Biotechnologies, Raises Price Target to $27.5

Piper Sandler analyst David Westenberg maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Overweight and raises the price target from $20 to $27.5.
Benzinga Newsdesk

PRO
Morgan Stanley Maintains Equal-Weight on Adaptive Biotechnologies, Raises Price Target to $22

Morgan Stanley analyst Tejas Savant maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Equal-Weight and raises the price target from $20 to $22.
Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $28

TD Cowen analyst Dan Brennan maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $25 to $28.
Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $25

Guggenheim analyst Subbu Nambi maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $22 to $25.
Benzinga Newsdesk

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

시장 데이터 제공 Benzinga API

BenzingaBenzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved